Antioxidants in the Treatment of Amyloidosis: a Literature Review
Article Sidebar
Main Article Content
Abstract
Introduction: The primary objective of this review is to examine the current scientific evidence regarding
the role of antioxidants in relation to amyloidosis. Oxidative stress has been studied in amyloidosis, and a narrative review of articles concerning the use of antioxidants in the treatment of these diseases was conducted.
State of the Art: Articles published from 2010 to 2022 are presented, focusing on the use of carvedilol,
epigallocatechin gallate (EGCG), resveratrol, and tetracyclines in amyloidosis models and cases.
Discussion/Conclusion: Antioxidant therapy for amyloidosis is in its early stages of development,
requiring further clinical studies to assess long-term effectiveness and safety. Antioxidants such as
carvedilol and EGCG show significant potential in interfering with amyloid fibrils, but additional research is needed to fully comprehend their impact and viability as long-term treatments.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2020;27(4):217-222. https://doi.org/10.1080/13506129.2020.1835263. DOI: https://doi.org/10.1080/13506129.2020.1835263
Persson T, Popescu BO, Cedazo-Minguez A. Oxidative stress in Alzheimer's disease: why did antioxidant therapy fail? Oxid Med Cell Longev. 2014;2014:427318. https://doi.org/10.1155/2014/427318. DOI: https://doi.org/10.1155/2014/427318
Bouayed J, Bohn T. Exogenous antioxidants--double-edged swords in cellular redox state: health beneficial effects at physiologic doses versus deleterious effects at high doses. Oxid Med Cell Longev. 2010;3(4):228-237. https://doi.org/10.4161/oxim.3.4.12858. DOI: https://doi.org/10.4161/oxim.3.4.12858
Ando Y, Nyhlin N, Suhr O, et al. Oxidative stress is found in amyloid deposits in systemic amyloidosis. Biochem Biophys Res Commun. 1997;232(2):497-502. https://doi.org/10.1006/bbrc.1996.5997. DOI: https://doi.org/10.1006/bbrc.1996.5997
Sousa MM, Cardoso I, Fernandes R, et al. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol. 2001;159(6):1993-2000. https://doi.org/10.1016/s0002-9440(10)63050-7. DOI: https://doi.org/10.1016/S0002-9440(10)63050-7
Sousa MM, Fernandes R, Palha JA, et al. Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro. Am J Pathol. 2002;161(5):1935-1948. https://doi.org/10.1016/S0002-9440(10)64469-0. DOI: https://doi.org/10.1016/S0002-9440(10)64469-0
Laboratorios Bagó. Carvedil 3,125 - 6,25 - 12,5 - 25 – 50; Carvedilol 3,125 - 6,25 - 12,5 - 25 - 50 mg [Internet]. Buenos Aires: Bagó; 202? [citado 2023 ago 14]. Disponible en: https://www.bago.com.ar/vademecum/prospectos/carvedil_prospecto.pdf.
Macedo B, Magalhães J, Batista AR, et al. Carvedilol treatment reduces transthyretin deposition in a familial amyloidotic polyneuropathy mouse model. Pharmacol Res. 2010;62(6):514-522. https://doi.org/10.1016/j.phrs.2010.08.001. DOI: https://doi.org/10.1016/j.phrs.2010.08.001
Wada Y, Kobayashi D, Murakami S, et al. Cardiac AA amyloidosis in a patient with rheumatoid arthritis and systemic sclerosis: the therapeutic potential of biological reagents. Scand J Rheumatol. 2011;40(5):402-404. https://doi.org/10.3109/03009742.2011.569754. DOI: https://doi.org/10.3109/03009742.2011.569754
Imamura T, Izumida T, Hori M, et al. Combination therapy using tafamidis and neurohormonal blockers for cardiac amyloidosis and a reduced ejection fraction: a case report. J Int Med Res. 2022;50(7):3000605221078484. https://doi.org/10.1177/03000605221078484. DOI: https://doi.org/10.1177/03000605221078484
Barge-Caballero G, Barge-Caballero E, López-Pérez M, et al. Beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy. Mayo Clin Proc. 2022;97(2):261-273. https://doi.org/10.1016/j.mayocp.2021.08.006. DOI: https://doi.org/10.1016/j.mayocp.2021.08.006
ANMAT. Disposición 6267-20 [Internet]. Buenos Aires: ANMAT; 2020 ago 25 [citado 2023 ago 14]. Disponible en: https://boletin.anmat.gob.ar/agosto_2020/Dispo_6267-20.pdf.
Ferreira N, Saraiva MJ, Almeida MR. Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "in vivo" evidence from FAP mice models. PLoS One. 2012;7(1):e29933. https://doi.org/10.1371/journal.pone.0029933. DOI: https://doi.org/10.1371/journal.pone.0029933
Meshitsuka S, Shingaki S, Hotta M, et al. Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis. Int J Hematol. 2017;105(3):295-308. https://doi.org/10.1007/s12185-016-2112-1. DOI: https://doi.org/10.1007/s12185-016-2112-1
aus dem Siepen F, Bauer R, Aurich M, et al. Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. Drug Des Devel Ther. 2015;9:6319-6325. https://doi.org/10.2147/DDDT.S96893. DOI: https://doi.org/10.2147/DDDT.S96893
González-López E, López-Sainz Á. García-Pavia P. Diagnóstico y tratamiento de la amiloidosis cardiaca por transtiretina: progreso y esperanza. Rev Esp Cardiol. 2017;70(11):991-1004. https://doi.org/10.1016/j.recesp.2017.05.018. DOI: https://doi.org/10.1016/j.recesp.2017.05.018
Nuvolone M, Merlini G. Systemic amyloidosis: novel therapies and role of biomarkers. Nephrol Dial Transplant. 2017;32(5):770-780. https://doi.org/10.1093/ndt/gfw305. DOI: https://doi.org/10.1093/ndt/gfw305
Asociación Española de Pediatría. Comité de Medicamentos. Pediamecum: tetraciclina [Internet]. Madrid: AEP; 2015 [citado 2023 ago 14]. Disponible en: https://www.aeped.es/comite-medicamentos/pediamecum/tetraciclina.
Miyachi Y, Yoshioka A, Imamura S, et al. Effect of antibiotics on the generation of reactive oxygen species. J Invest Dermatol. 1986;86(4):449-453. https://doi.org/10.1111/1523-1747.ep12285793. DOI: https://doi.org/10.1111/1523-1747.ep12285793
Stoilova T, Colombo L, Forloni G, et al. A new face for old antibiotics: tetracyclines in treatment of amyloidoses. J Med Chem. 2013;56(15):5987-6006. https://doi.org/10.1021/jm400161p. DOI: https://doi.org/10.1021/jm400161p
Abdallah N, Dispenzieri A, Muchtar E, et al. The impact of post-transplant doxycycline in AL amyloidosis - updated results after long-term follow up. Amyloid. 2023;30(3):261-267. https://doi.org/10.1080/13506129.2022.2155809. DOI: https://doi.org/10.1080/13506129.2022.2155809
Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554-1568. https://doi.org/10.1093/eurheartj/ehab072. DOI: https://doi.org/10.1093/eurheartj/ehab072
Villanueva E, Carretero M, Aguirre MA, et al. Guía de tratamiento farmacológico específico de la cardiomiopatía amiloidótica por transtiretina, 2021. Medicina (B Aires). 2022;82(2):275-288.
Gambini J, López-Grueso R, Olaso-González G, et al. Resveratrol: distribución, propiedades y perspectivas. Rev Esp Geriatr Gerontol. 2013;48(2):79-88. https://doi.org/10.1016/j.regg.2012.04.007. DOI: https://doi.org/10.1016/j.regg.2012.04.007
Bourgault S, Choi S, Buxbaum JN, et al. Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochem Biophys Res Commun. 2011;410(4):707-713. https://doi.org/10.1016/j.bbrc.2011.04.133. Errata en: Biochem Biophys Res Commun. 2011;412(1):196. DOI: https://doi.org/10.1016/j.bbrc.2011.07.093
Celik G, Capraz I, Yontem M, et al. The relationship between the antioxidant system, oxidative stress and dialysis-related amyloidosis in hemodialysis patients. Saudi J Kidney Dis Transpl. 2013;24(6):1157-1164. https://doi.org/10.4103/1319-2442.121272. DOI: https://doi.org/10.4103/1319-2442.121272